Long-term outcome of the in situ versus free internal thoracic artery as the second arterial graft.


Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
12 2021
Historique:
received: 25 08 2019
revised: 21 02 2020
accepted: 02 03 2020
pubmed: 20 4 2020
medline: 30 12 2021
entrez: 20 4 2020
Statut: ppublish

Résumé

The study objective was to determine the impact on outcome associated with using the second internal thoracic artery as a free compared with an in situ graft among patients who received the first internal thoracic artery as an in situ internal thoracic artery to the left anterior descending artery. Among 2600 patients who underwent bilateral internal thoracic artery with an in situ internal thoracic artery to the left anterior descending artery, the second internal thoracic artery was used as a free graft bilateral internal thoracic artery in 136 patients and as an in situ graft (in situ bilateral internal thoracic artery) in 2464 patients. One-to-many propensity score matching was performed to produce a cohort of 134 patients with a second free graft internal thoracic artery matched to 2359 patients with a second in situ internal thoracic artery. Early and long-term outcomes including survival, hospital readmission, and repeat revascularization up to a maximum of 25.8 years were compared. There were no differences between the 2 matched groups' preoperative baseline characteristics and early adverse events. Long-term survival at 5, 10, and 15 years was significantly higher among patients with an in situ bilateral internal thoracic artery compared with patients with a free graft bilateral internal thoracic artery (hazard ratio free graft bilateral internal thoracic artery vs in situ bilateral internal thoracic artery, 1.53; 95% confidence interval, 1.14-2.10; P = .004). However, the long-term risk of readmission to the hospital for cardiovascular reasons and need for repeat revascularization were not significantly different between the 2 matched groups. In a small, propensity-matched cohort of patients undergoing coronary artery bypass grafting, the use of a second in situ internal thoracic artery was associated with an increase in late survival compared with the use of a second internal thoracic artery as a free graft. However, the risk of late hospital readmission and the need for repeat revascularization were similar.

Identifiants

pubmed: 32305200
pii: S0022-5223(20)30549-3
doi: 10.1016/j.jtcvs.2020.03.003
pii:
doi:

Types de publication

Comparative Study Journal Article Observational Study Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

1744-1752.e7

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Mohamed Marzouk (M)

Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Dimitri Kalavrouziotis (D)

Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Valentina Grazioli (V)

Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Christophe Meneas (C)

Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Joseph Nader (J)

Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Serge Simard (S)

Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Siamak Mohammadi (S)

Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada. Electronic address: siamak.mohammadi@fmed.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH